Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Daré Bioscience Announces Efficacy Results From The DARE-HRT1 Phase 1 / 2 Study

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause   DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both
byBenzinga Newsdesk
October 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause
 

DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Canopy Growth Doubles Down On Its USA Strategy, Announces Exercise of Acreage Options

By Jelena Martinovic
June 4, 12:51 PM
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) announced on Tuesday today that the option to acquire all of the issued and outstanding Class E subordinate voting shares of Acreage Holdings, Inc. (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), has been exercised.The latest move is by the terms of the arrangement agreement dated April 18, 2019, as amended, between Canopy Growth and Acreage.In connection with the arrangement agreement dated October 24, 2022, by and among Canopy Growth, Canopy USA, LLC and Acreage, as amended, in respect of the Class D subordinate voting shares of Acreage, on closing, Canopy USA will acquire all of the fixed shares and floating shares and Acreage will become a wholly-owned subsidiary of Canopy USA.

ACRDF

Read More

Coya Announces Acceptance Of Oral Presentation, “Regulatory T Cell Expansion Strategy To Target Inflammation In Alzheimer’s Disease: A Phase 1 Feasibility Study,” At The 18th International Conference On Alzheimer’s And Parkinson’s Disease In Lisbon

By Benzinga Newsdesk
October 27, 9:01 AM
Alireza Faridar, MD (Houston Methodist and Weill Cornell Medical College) will present data from an open-label, proof-of-concept study in 8 AD patients treated with Low Dose IL-2 (LD IL-2) over a 4 month period that

COYA